Karyopharm Therapeutics Inc
WKN: A40YLC / ISIN: US48576U2050A1W77U
| eröffnet am: | 09.04.14 14:07 von: | Balu4u |
| neuester Beitrag: | 24.07.25 12:21 von: | moneywork4me |
| Anzahl Beiträge: | 95 | |
| Leser gesamt: | 54760 | |
| davon Heute: | 19 | |
bewertet mit 2 Sternen |
||
|
Seite:
1
|
2
|
||
Zahlen für Q3/19
- Umsätze 13 Mio. $
- Verlust 41 Mio. $
- Cash 270 Mio. $
- MK 857 Mio. $
- im Februar/März stand Karyopharm noch bei 4$
- bald Kapitalerhöhung?
"Strengthened Balance Sheet with Cash Runway Expected to be Sufficient to Fund
Operations into the Middle of 2021"
https://investors.karyopharm.com/news-releases/...nancial-results-and
https://www.fool.com/investing/2019/12/20/...ck-take-off-in-2020.aspx
positive Selinexor Daten
https://investors.karyopharm.com/news-releases/...ts-primary-endpoint
FDA Zulassung für XPOVIO® (selinexor) in DLBCL
https://investors.karyopharm.com/news-releases/...selinexor-treatment
Zahlen für Q2/20
- Umsatz 34 Mio. $
- Verlust 46 Mio. $
- Cash 348 Mio. $
- MK 1,15 Mrd. $
"The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, will be sufficient to fund its planned operations into the middle of 2022"
https://investors.karyopharm.com/news-releases/...nancial-results-and
Zahlen für Q3/20
- Umsatz 21 Mio. $
- Verlust 53 Mio. $
- Cash 304 Mio. $
- MK 1,07 Mrd. $
- positive Phase3 SEAL-Studienergebnisse
"The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, will be sufficient to fund its planned operations into the second half of 2022."
https://investors.karyopharm.com/...ighlights-Recent-Company-Progress
https://investors.karyopharm.com/...able-Dedifferentiated-Liposarcoma
Karyopharm Therapeutics Inc. (KPTI) has secured approval for XPOVIO in Israel for the treatment of patients with either multiple myeloma or diffuse large B-cell lymphoma.
The company has an exclusive distribution agreement with Promedico Ltd. for the commercialization of XPOVIO in Israel and the Palestinian Authority. The drug received its initial approval in the U.S. in July 2019, and is under review by the European Medicines Agency.
Karyopharm is slated to report fourth quarter and full year 2020 financial results on Thursday, February 11, 2021.
The net product sales of XPOVIO are expected to be between $20.0 million and $20.5 million for the fourth quarter of 2020 and between $76.0 million and $76.5 million for the full year of 2020. The sales of XPOVIO were $17.7 million for the fourth quarter and $30.5 million for full year 2019.
KPTI closed Thursday's trading at $14.60, down 1.08%.
https://www.finanznachrichten.de/...s-footprint-otlk-on-track-020.htm
Zahlen für Q4/20
- Umsatz 35 Mio. $
- Verlust 43 Mio. $
- Cash 277 Mio. $
- MK 1,01 Mrd. $
"The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, as well as revenue generated from its license agreements, will be sufficient to fund its planned operations into late 2022"
https://investors.karyopharm.com/...ighlights-Recent-Company-Progress
bedingte EU Zulassung für NEXPOVIO® (selinexor)
https://investors.karyopharm.com/...nd-or-Refractory-Multiple-Myeloma
sehr seltsam ist die lange Liste an Insider-Verkäufen in den letzten Monaten
https://www.gurufocus.com/stock/KPTI/insider?search=karyopharm
Zahlen für Q1/21
- Umsatz 23 Mio. $
- Verlust 57 Mio. $
- Cash 234 Mio. $
- MK 623 Mio. $
Conditional Marketing Authorization Granted by the European Commission for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma;
European Decision for Expanded Multiple Myeloma Indication Expected in the Fourth Quarter of 2021
https://investors.karyopharm.com/...ighlights-Recent-Company-Progress
http://www.healthcareroyalty.com/...re-royalty-for-up-to-100-million/
und der Kurs steigt mal gerade um 3%, so wie viele Buden gestern ohne News...
Damit keine Verwässerung bis 2023 zu befürchten.
Zahlen für Q2/21
- Umsätze 22,6 Mio. $
- davon XPOVIO® (selinexor) 20,2 Mio. $ (-7% zum Vorquartal)
- davon XPOVIO® (selinexor) 20,2 Mio. $ (-7% zum Vorquartal)
- Verlust 54 Mio. $
- Cash 239 Mio. $
- MK 587 Mio. $ (SK von gestern)
- Looking Forward to a Milestone-Driven Second Half of 2021, Including Top-Line Data from Phase 3 SIENDO Study in Endometrial Cancer and Initiations and Expansions of Key Clinical Trials in Myelodysplastic Syndrome, Myelofibrosis, Multiple Myeloma & Colorectal Cancer
https://investors.karyopharm.com/...nd-Quarter-2021-Financial-Results
Das sehen die Marktteilnehmer äußerst ungern, wenn die Umsatzzahlen eines neuen Produktes fallen statt zu steigen. Die Q1/21 Produktumsätze lagen bei 21,7 Mio. $.
1
|